Interferon-β 1a and SARS Coronavirus Replication

A global outbreak of severe acute respiratory syndrome (SARS) caused by a novel coronavirus began in March 2003. The rapid emergence of SARS and the substantial illness and death it caused have made it a critical public health issue. Because no effective treatments are available, an intensive effort...

Descripción completa

Detalles Bibliográficos
Autores principales: Hensley, Lisa E., Fritz, Elizabeth A., Jahrling, Peter B., Karp, Christopher, Huggins, John W., Geisbert, Thomas W.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Centers for Disease Control and Prevention 2004
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3322919/
https://www.ncbi.nlm.nih.gov/pubmed/15030704
http://dx.doi.org/10.3201/eid1002.030482
Descripción
Sumario:A global outbreak of severe acute respiratory syndrome (SARS) caused by a novel coronavirus began in March 2003. The rapid emergence of SARS and the substantial illness and death it caused have made it a critical public health issue. Because no effective treatments are available, an intensive effort is under way to identify and test promising antiviral drugs. Here, we report that recombinant human interferon (IFN)-β 1a potently inhibits SARS coronavirus replication in vitro.

Ejemplares similares